

on the labeling of, a controlled substance being utilized in clinical research involving blind and double blind studies.

[36 FR 7785, Apr. 24, 1971, as amended at 36 FR 18731, Sept. 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973]

§ 1302.04 Location and size of symbol on label and labeling.

The symbol shall be prominently located on the label or the labeling of the commercial container and/or the panel of the commercial container normally displayed to dispensers of any controlled substance. The symbol on labels shall be clear and large enough to afford easy identification of the schedule of the controlled substance upon inspection without removal from the dispenser's shelf. The symbol on all other labeling shall be clear and large enough to afford prompt identification of the controlled substance upon inspection of the labeling.

[62 FR 13958, Mar. 24, 1997]

§ 1302.05 Effective dates of labeling requirements.

All labels on commercial containers of, and all labeling of, a controlled substance which either is transferred to another schedule or is added to any schedule shall comply with the requirements of § 1302.03, on or before the effective date established in the final order for the transfer or addition.

[62 FR 13958, Mar. 24, 1997]

§ 1302.06 Sealing of controlled substances.

On each bottle, multiple dose vial, or other commercial container of any controlled substance, there shall be securely affixed to the stopper, cap, lid, covering, or wrapper or such container a seal to disclose upon inspection any tampering or opening of the container.

[62 FR 13958, Mar. 24, 1997]

§ 1302.07 Labeling and packaging requirements for imported and exported substances.

(a) The symbol requirements of §§ 1302.03–1302.05 apply to every commercial container containing, and to all labeling of, controlled substances imported into the jurisdiction of and/or

the customs territory of the United States.

(b) The symbol requirements of §§ 1302.03–1302.05 do not apply to any commercial containers containing, or any labeling of, a controlled substance intended for export from the jurisdiction of the United States.

(c) The sealing requirements of § 1302.06 apply to every bottle, multiple dose vial, or other commercial container of any controlled substance listed in schedule I or II, or any narcotic controlled substance listed in schedule III or IV, imported into, exported from, or intended for export from, the jurisdiction of and/or the customs territory of the United States.

[62 FR 13958, Mar. 24, 1997]

PART 1303—QUOTAS

GENERAL INFORMATION

Sec.

- 1303.01 Scope of part 1303.
- 1303.02 Definitions.

AGGREGATE PRODUCTION AND PROCUREMENT QUOTAS

- 1303.11 Aggregate production quotas.
- 1303.12 Procurement quotas.
- 1303.13 Adjustments of aggregate production quotas.

INDIVIDUAL MANUFACTURING QUOTAS

- 1303.21 Individual manufacturing quotas.
- 1303.22 Procedure for applying for individual manufacturing quotas.
- 1303.23 Procedure for fixing individual manufacturing quotas.
- 1303.24 Inventory allowance.
- 1303.25 Increase in individual manufacturing quotas.
- 1303.26 Reduction in individual manufacturing quotas.
- 1303.27 Abandonment of quota.

HEARINGS

- 1303.31 Hearings generally.
- 1303.32 Purpose of hearing.
- 1303.33 Waiver or modification of rules.
- 1303.34 Request for hearing or appearance; waiver.
- 1303.35 Burden of proof.
- 1303.36 Time and place of hearing.
- 1303.37 Final order.

AUTHORITY: 21 U.S.C. 821, 826, 871(b).